{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-24-000087","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.157024+00:00","generated_at":"2026-06-03T02:51:44.487615+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Summit Therapeutics Q1 net loss $43.5M; cash $157M; ivonescimab shows 34% intracranial response in NSCLC brain mets","bullets":["GAAP net loss $43.5M ($0.06/sh) vs $542.3M ($1.43/sh) prior year; non-GAAP net loss $34.0M ($0.05/sh).","Cash and investments $157M at March 31; operating cash outflow $30.1M; guidance cash runway through Q1 2025.","R&D expenses $30.9M GAAP, up from $9.9M; non-GAAP R&D $28.5M as trial enrollment expands.","Ivonescimab Phase II data: 34% intracranial response rate; median intracranial PFS 19.3 months in NSCLC brain metastases; mPFS 11.1 months in first-line squamous NSCLC.","HARMONi (EGFR-mutant NSCLC) enrollment completion expected H2 2024; HARMONi-3 (first-line squamous) first patient treated Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-24-000087","json":"https://secwatch.observer/filing/0001599298-24-000087.json","markdown":"https://secwatch.observer/filing/0001599298-24-000087.md","text":"https://secwatch.observer/filing/0001599298-24-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000087/0001599298-24-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000087/smmt-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:51:44.487615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cbe5a84b2d18a9523b1bba300271184626d19da4","claim":"Summit Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 1, 2024, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000087/0001599298-24-000087-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}